Anti-VEGF Injections

The back of the eye needs a steady supply of oxygen. When part of the retina is starved of oxygen (from diabetes, age-related macular degeneration, or a blocked retinal vein), it sends out a chemical signal called VEGF — vascular endothelial growth factor. VEGF tells the body to grow new blood vessels. The trouble is that these new vessels are fragile and leaky, so they bleed and swell instead of helping ¹.

Anti-VEGF drugs are big proteins that grab onto VEGF in the eye and block it. With less VEGF around:

• Abnormal new blood vessels stop growing and slowly shrink.
• Fluid leaking under or into the retina dries up.
• Bleeding into the macula stops.
• Central vision often improves over weeks.

Because anti-VEGF drugs are big proteins, they cannot get into the eye through eye drops or pills — they have to be injected. The good news is that putting medicine directly into the eye means a tiny dose can work very well with almost no medicine reaching the rest of the body.

Retina specialists use anti-VEGF therapy for several conditions:

• Wet (neovascular) age-related macular degeneration. Anti-VEGF is the standard of care. Started early, it saves vision in most eyes and many people gain vision back ¹.
• Diabetic macular edema (DME). Anti-VEGF is the first-line treatment for swelling in the macula caused by diabetes. It works as well or better than older laser treatment ².
• Proliferative diabetic retinopathy (PDR). Anti-VEGF injections can replace or add to panretinal laser to shrink the abnormal new vessels.
• Macular edema from retinal vein occlusion (CRVO or BRVO). Anti-VEGF saves vision in most eyes with swelling after a clot in a retinal vein.
• Myopic choroidal neovascularization. Abnormal vessels in very high-myopia eyes respond very well to anti-VEGF.
• Retinopathy of prematurity in premature babies.
• Neovascular glaucoma and certain unusual forms of wet AMD (e.g., polypoidal choroidal vasculopathy), often combined with other treatments.

Several anti-VEGF medicines are available. Your retina specialist picks one based on your diagnosis, your insurance, your other health problems, and how your eye responds ³.

• Bevacizumab (Avastin) — first used as an off-label cancer drug. The cheapest option, often $50-$100 per injection. Major retina trials (CATT, IVAN) showed it works about as well as more expensive drugs for wet age-related macular degeneration. It is used off-label, since the drug is officially approved for cancer in the U.S.
• Ranibizumab (Lucentis, and biosimilars) — the first anti-VEGF designed for the eye. Newer biosimilar versions have lowered the price.
• Aflibercept (Eylea, Eylea HD) — blocks VEGF and another related signal (placental growth factor). Often allows a longer time between injections than older drugs. A higher-dose version (Eylea HD) was added to stretch dosing further.
• Faricimab (Vabysmo) — blocks VEGF and another signal called Ang-2. Newer drug; many patients reach injection intervals of 12-16 weeks.
• Brolucizumab (Beovu) — also designed to stretch out dosing, but linked with a small risk of intraocular inflammation, so it is used less often ¹.

For most patients, the bigger question is not which drug, but whether the disease stays under control on the schedule the doctor picks.

Anti-VEGF eye injections are very safe overall, but no procedure is risk-free. Most side effects are mild and short-lived ⁵:

• Gritty, scratchy feeling for a few hours from the antiseptic. Lubricating drops help.
• Red spot on the white of the eye (subconjunctival hemorrhage) where the needle went in. Fades over 1-2 weeks.
• New floaters for a day or two from a tiny bit of medicine in the vitreous.
• Temporary rise in eye pressure for a few minutes after the shot.
• Mild blurry vision for a few hours.

Serious side effects are rare but important:

• Endophthalmitis (eye infection) — happens about 1 in every 3,000-5,000 injections. Symptoms are increasing pain, vision drop, and severe redness in the days after the shot. Call the retina office right away — this is treatable with antibiotics if caught fast ⁶.
• Intraocular inflammation (uveitis or vitritis) — slightly higher risk with brolucizumab; usually treated with steroid drops.
• Retinal detachment or tear — very rare.
• Cataract or worsened cataract — uncommon with modern technique.
• Theoretical risk of stroke or heart attack — large trials have not found a clear increase, but injections are usually delayed for 1-3 months after a fresh stroke, heart attack, or blood clot.

What anti-VEGF treatment costs in the U.S.:

• Bevacizumab (Avastin, off-label): roughly $50-$100 per dose.
• Ranibizumab (Lucentis): roughly $1,200-$1,900 per dose; biosimilars are cheaper.
• Aflibercept (Eylea): roughly $1,800-$2,000 per dose; Eylea HD is similar.
• Faricimab (Vabysmo): roughly $2,000-$2,200 per dose.
• Plus an office or facility fee for the visit, OCT imaging, and the injection procedure.

Most people get many injections over time, so total cost adds up. Insurance usually covers a large share of the drug and visit cost when the diagnosis is appropriate.

What insurance usually covers:

• Medicare covers anti-VEGF for the approved retinal conditions listed above, with the patient usually paying about 20% under Part B unless they have a Medigap or Medicare Advantage plan.
• Private insurance almost always covers anti-VEGF for wet age-related macular degeneration, diabetic macular edema, and vein occlusion, with a copay or coinsurance that depends on the plan.
• Manufacturer copay programs can lower out-of-pocket costs to as little as $0 per dose for patients with commercial insurance.
• Bevacizumab is often the lowest cost option for both patient and insurer.
• Patient assistance programs (PAN Foundation, Good Days, the manufacturers' foundations) can help cover Medicare copays.

Ask the practice's billing team for a written estimate before you start treatment. Costs can change as biosimilars are released and as new drugs and dosing schedules become available.